Display options
Cite
Müller E, Christopoulos PF, Halder S, et al. Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages. Front Immunol. 2017;8:1383doi: 10.3389/fimmu.2017.01383.
Müller, E., Christopoulos, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M., Øynebråten, I., & Corthay, A. (2017). Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages. Frontiers in immunology, 81383. https://doi.org/10.3389/fimmu.2017.01383
Müller, Elisabeth, et al. "Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages." Frontiers in immunology vol. 8 (2017): 1383. doi: https://doi.org/10.3389/fimmu.2017.01383
Müller E, Christopoulos PF, Halder S, Lunde A, Beraki K, Speth M, Øynebråten I, Corthay A. Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages. Front Immunol. 2017 Oct 26;8:1383. doi: 10.3389/fimmu.2017.01383. eCollection 2017. PMID: 29123526; PMCID: PMC5662546.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Oct 26;8:1383. doi: 10.3389/fimmu.2017.01383. eCollection 2017.

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages.

Frontiers in immunology

Elisabeth Müller, Panagiotis F Christopoulos, Sanjib Halder, Anna Lunde, Kahsai Beraki, Martin Speth, Inger Øynebråten, Alexandre Corthay

Affiliations

  1. Tumor Immunology Lab, Department of Pathology, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway.
  2. Department of Biosciences, University of Oslo, Oslo, Norway.

PMID: 29123526 PMCID: PMC5662546 DOI: 10.3389/fimmu.2017.01383

Abstract

Tumor-associated macrophages may either promote or suppress tumor growth depending on their activation status. Interferon-γ (IFN-γ) has been identified as a key factor for inducing tumoricidal M1 phenotype in macrophages. However, it remains unclear whether IFN-γ is sufficient or if additional stimuli are required. Here, we tested IFN-γ and a panel of toll-like receptor (TLR) agonists for the ability to activate murine macrophages toward a tumoricidal M1 phenotype. The following TLR ligands were used: TLR1/TLR2 agonist Pam3CSK4, TLR2/TLR6 agonist lipotechoic acid, TLR3 agonist poly(I:C), TLR4 agonist lipopolysaccharide (LPS), TLR5 agonist flagellin, TLR7 agonist CL264, and TLR9 agonist CpG. We used an

Keywords: cancer; immunotherapy; interferon-γ; macrophages; nitric oxide; toll-like receptors; tumoricidal

References

  1. J Immunol. 1978 Jul;121(1):72-80 - PubMed
  2. Mol Immunol. 2011 Sep;48(15-16):2170-7 - PubMed
  3. F1000Prime Rep. 2014 Mar 03;6:13 - PubMed
  4. Nat Immunol. 2010 Oct;11(10):889-96 - PubMed
  5. Immunology. 2007 Mar;120(3):412-23 - PubMed
  6. Cell Immunol. 1978 Nov;41(1):35-51 - PubMed
  7. J Interferon Res. 1987 Apr;7(2):165-71 - PubMed
  8. Arch Pharm Res. 2014;37(9):1234-40 - PubMed
  9. Front Immunol. 2014 Oct 27;5:532 - PubMed
  10. Biochem Biophys Res Commun. 2007 Mar 23;354(4):1045-51 - PubMed
  11. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3782-6 - PubMed
  12. J Leukoc Biol. 2000 May;67(5):677-82 - PubMed
  13. Science. 1977 Jul 15;197(4300):279-82 - PubMed
  14. Biochem Biophys Res Commun. 1988 Nov 30;157(1):87-94 - PubMed
  15. J Biochem. 1997 Jan;121(1):38-46 - PubMed
  16. Nature. 1972 Mar 24;236(5343):168-70 - PubMed
  17. Clin Exp Immunol. 2006 Oct;146(1):181-8 - PubMed
  18. Infect Immun. 2003 Jun;71(6):3053-7 - PubMed
  19. Nat New Biol. 1971 Jul 21;232(29):76-8 - PubMed
  20. Cancer Lett. 1980 Nov;11(1):63-73 - PubMed
  21. Nat Med. 2013 Oct;19(10):1264-72 - PubMed
  22. CSH Protoc. 2008 Dec 01;2008:pdb.prot5080 - PubMed
  23. Nat Rev Clin Oncol. 2017 Jul;14 (7):399-416 - PubMed
  24. Nat Commun. 2011;2:240 - PubMed
  25. Cancer Immunol Immunother. 2012 Oct;61(10):1683-97 - PubMed
  26. J Mol Cell Biol. 2012 Oct;4(5):341-3 - PubMed
  27. Trends Immunol. 2002 Nov;23(11):549-55 - PubMed
  28. Infect Immun. 2001 May;69(5):2847-52 - PubMed
  29. Curr Opin Immunol. 2010 Apr;22(2):231-7 - PubMed
  30. J Natl Cancer Inst. 1948 Dec;9(3):229-46 - PubMed
  31. J Pathol. 2013 Jan;229(2):176-85 - PubMed
  32. Nature. 1970 Nov 14;228(5272):620-2 - PubMed
  33. Immunology. 2011 Feb;132(2):226-39 - PubMed
  34. J Leukoc Biol. 2009 Apr;85(4):664-72 - PubMed
  35. Science. 2011 Mar 25;331(6024):1612-6 - PubMed
  36. Oncoimmunology. 2012 Oct 1;1(7):1146-1155 - PubMed
  37. Scand J Immunol. 2006 Aug;64(2):83-92 - PubMed
  38. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2066-71 - PubMed
  39. Cell Signal. 2009 Jun;21(6):978-85 - PubMed
  40. J Immunol. 2006 Jan 1;176(1):309-18 - PubMed
  41. Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 - PubMed
  42. Oncoimmunology. 2015 Sep 2;5(3):e1088631 - PubMed
  43. Science. 1987 Jan 23;235(4787):473-6 - PubMed
  44. Immunity. 2014 Jul 17;41(1):14-20 - PubMed
  45. J Immunol. 2015 May 1;194(9):4215-21 - PubMed
  46. Proc Natl Acad Sci U S A. 1972 Nov;69(11):3124-7 - PubMed
  47. J Leukoc Biol. 2012 Aug;92(2):325-31 - PubMed
  48. J Immunol. 1990 Apr 1;144(7):2725-9 - PubMed
  49. Immunity. 2006 May;24(5):563-74 - PubMed
  50. Immunity. 2005 Mar;22(3):371-83 - PubMed
  51. J Immunol. 1981 Jul;127(1):179-83 - PubMed
  52. J Cell Biochem. 2010 Dec 15;111(6):1522-30 - PubMed
  53. Nature. 2017 Mar 16;543(7645):428-432 - PubMed
  54. PLoS One. 2013 Nov 15;8(11):e80908 - PubMed
  55. Oncoimmunology. 2014 May 23;3:e28926 - PubMed
  56. Immunity. 1999 Jan;10(1):39-49 - PubMed
  57. J Immunol. 1980 Feb;124(2):708-12 - PubMed
  58. J Exp Med. 1989 May 1;169(5):1543-55 - PubMed
  59. Cancer Res. 1994 May 1;54(9):2462-7 - PubMed
  60. J Interferon Cytokine Res. 1995 May;15(5):387-94 - PubMed
  61. Nature. 2016 Nov 17;539(7629):437-442 - PubMed
  62. J Clin Invest. 1995 Nov;96(5):2339-47 - PubMed
  63. Cancer Lett. 2013 May 1;331(2):239-49 - PubMed
  64. Biochem Biophys Res Commun. 1985 Aug 30;131(1):395-401 - PubMed
  65. J Immunol. 1981 May;126(5):1863-7 - PubMed
  66. Nat Rev Immunol. 2008 Dec;8(12):958-69 - PubMed
  67. Br J Pharmacol. 1995 Jan;114(2):510-6 - PubMed
  68. J Immunol. 1985 Feb;134(2):977-81 - PubMed
  69. Semin Immunol. 2015 Aug;27(4):237-48 - PubMed
  70. Environ Health Perspect. 2009 Sep;117(9):1344-50 - PubMed
  71. Immunity. 2014 Feb 20;40(2):274-88 - PubMed
  72. J Immunol. 1983 Aug;131(2):826-32 - PubMed
  73. J Immunol. 1977 Sep;119(3):950-54 - PubMed
  74. Nat Rev Immunol. 2007 May;7(5):353-64 - PubMed
  75. J Cell Sci. 2004 Jun 15;117(Pt 14):2865-7 - PubMed
  76. J Leukoc Biol. 1993 Oct;54(4):322-8 - PubMed
  77. J Immunol. 2012 Feb 15;188(4):1592-9 - PubMed
  78. J Immunol. 1992 Oct 15;149(8):2709-14 - PubMed
  79. Infect Immun. 1992 Sep;60(9):3664-72 - PubMed
  80. BMB Rep. 2016 Jun;49(6):305-10 - PubMed
  81. Mediators Inflamm. 2013;2013:931562 - PubMed
  82. J Immunol. 2000 Jun 15;164(12):6166-73 - PubMed

Publication Types